New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.00% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−113.8%−128.9%−169.1%−212.3%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 4.08× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA3.4×4.1×2.9×4.1×
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
ROE
(212.27%) (169.09%) (128.90%) (113.78%)

+8 more TTM periods

ROA
(69.68%) (69.20%) (61.53%) (55.28%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(66,164.00%) (810.41%) (243.65%) (158.14%)
Free Cash Flow per Share
(10.14) (10.43) (9.37) (9.56)
Free Cash Flow
(32.62) (33.48) (30.04) (30.34)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 12, 2026